SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA.

Authors :: Nikkarinen, A.
Lokhande, L.
Amini, R.
Jerkeman, M.
Porwit, A.
Molin, D.
Enblad, G.
Kolstad, A.
Räty, R.
Hutchings, M.
Weibull, C. E.
Hollander, P.
Ek, S.
Glimelius, I.
Source :: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p746-748, 3p
Publication Year :: 2023
Abstract: B Conclusion: b Our results show that a high level of the M2 macrophage marker sCD163 is a negative prognostic factor in MCL, both in the chemoimmunotherapy and the ibrutinib/lenalidomide eras. B Introduction: b The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed towards the tumor immune microenvironment, where macrophages play an important role. [Extracted from the article]

Full Text Access

Tools